Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cingulate Inc. Warrants (CINGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CINGW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.71% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.86 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/19/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -114.14% | Return on Equity (TTM) -358.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4237731 |
Shares Outstanding - | Shares Floating 4237731 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Cingulate Inc. Warrants
Company Overview
History and Background
Cingulate Inc. is a biopharmaceutical company focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD). The warrants represent the right to purchase shares of Cingulate's common stock at a specified price and time.
Core Business Areas
- Pharmaceutical Development: Focused on developing and commercializing novel therapies for ADHD.
Leadership and Structure
Details about Cingulate's leadership team and organizational structure are publicly available via their investor relations website and SEC filings.
Top Products and Market Share
Key Offerings
- CTX-1301: CTX-1301 is Cingulate's lead product candidate, an oral immediate-release formulation of dexmethylphenidate. Market share data is not yet applicable as the product is still under development. Competitors include other ADHD medications like Adderall and Ritalin.
- CTX-1302: CTX-1302 is Cingulate's other leading product candidate, focusing on extended release ADHD medication. Market share data is not applicable as it is under development. Competitors include Concerta and Vyvanse.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on ADHD treatments is characterized by significant demand and ongoing research and development.
Positioning
Cingulate aims to differentiate itself through innovative formulations with potential for improved efficacy and safety profiles.
Total Addressable Market (TAM)
The ADHD treatment market is estimated to be in the billions of dollars. Cingulate is positioned to capture a portion of this TAM with successful product launches.
Upturn SWOT Analysis
Strengths
- Novel product candidates
- Experienced management team
- Focus on unmet needs in ADHD treatment
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new ADHD-related indications
Threats
- Regulatory hurdles
- Clinical trial failures
- Generic competition
Competitors and Market Share
Key Competitors
- TEVA
- ALKS
- SHPG
Competitive Landscape
Cingulate faces intense competition from established pharmaceutical companies with larger resources and existing ADHD treatments. Cingulate needs FDA approval and successful clinical trial results to compete.
Growth Trajectory and Initiatives
Historical Growth: N/A (Development-stage company)
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing CTX-1301 and CTX-1302 through clinical trials.
Summary
Cingulate Inc. Warrants represent a speculative investment tied to the success of Cingulate's ADHD drug development program. As a development-stage company, Cingulate is dependent on securing funding and the successful completion of clinical trials. Positive clinical trial results and subsequent FDA approval would create substantial shareholder value. However, regulatory hurdles and clinical trial failures could significantly impact Cingulate's prospects. Investors should carefully consider the risks associated with investing in development-stage pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cingulate Inc. Warrants
Exchange NASDAQ | Headquaters Kansas City, KS, United States | ||
IPO Launch date 2021-12-08 | Co-Founder, CEO & Chairman of the Board Dr. Shane J. Schaffer Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.cingulate.com |
Full time employees 13 | Website https://www.cingulate.com | ||
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.